MS drug trial halted early after only 8 volunteers
NCT ID NCT04625153
First seen May 07, 2026 · Last updated May 23, 2026 · Updated 3 times
Summary
This phase 2 trial tested an experimental drug called RC18 in people with relapsing-remitting multiple sclerosis (MS). The goal was to see if RC18 is safe and can reduce the number of MS attacks. Only 8 people took part before the study was stopped early. The drug works by targeting a protein involved in the immune system to help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS, RELAPSING-REMITTING are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
the Third Affiliated Hospital,Sun Yat-Sen University
Guangzhou, Guangdong, China
Conditions
Explore the condition pages connected to this study.